Calliditas: FDA grants priority review for Nefecon with fixed 15th September PDUFA goal date
Research Note
2021-04-28
14:04
FDA's granted priority review supports Redeye's positive view on Calliditas. Our focus is now firmly on the commercial launch and reimbursement process for the lead candidate Nefecon.
JU
Johan Unnerus
Disclosures and disclaimers